Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis

Moxifloxacin injection for AECB

Authors

  • Tiantuo Zhang Department of Respiratory, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou China
  • Ping Chen Department of Respiratory, The Second Xiangya Hospital of Central South University, Changsha, China
  • Chengshui Chen Department of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • Jiulong Kuang Department of Respiratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • Changzheng Wang Department of Respiratory, Xinqiao Hospital, The Third Military Medical University, Chongqing, China
  • Xixin Yan Department of Respiratory, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
  • Xiaohong Yang Department of Respiratory, People's Hospital of Xinjiang Uygur Autonomous Regin, Urumqi, China
  • Yuxia Shao Department of Respiratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
  • Xiaochun Yang Department of Respiratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Keywords:

Efficacy, moxifloxacin injection, multi-center, safety

Abstract

Objective: To evaluate the clinical efficacy and safety of moxifloxacin injection in the treatment of acute exacerbation of chronic bronchitis (AECB) in daily clinical practice. Patients and Methods: From May 2009 to March 2011, a total of 1026 cases with AECB were collected from 43 hospitals in eight cities. All the patients were treated with moxifloxacin (400 mg qd) intravenously. Whether to use oral or sequential therapy was decided by the physicians according to the clinical efficacies. Patient conditions such as combined uses of drugs, efficacies and adverse events were recorded and analyzed. Results: The cure rate of infection was 83.03%, and the total effective rate of moxifloxacin injection was 93.80%. The efficacies were statistically different among subgroups with different ages, complications, forced expiratory volume in 1 s (FEV 1 %), and combined uses of drugs, respectively. Multivariable logistic regression analysis showed that the advanced age (≥65 years) and severe obstructive pulmonary disease (FEV 1 <50%) were significantly correlated with the clinical efficacies. A total of 15 cases of adverse events were recorded, and the incidence rate was 1.23%. Conclusion: Moxifloxacin injection can effectively control the infection of AECB patients with fewer adverse events.

References

Chronic Obstructive Pulmonary Disease Group, Respiratory Society, Chinese Medical Association. Guideline for diagnosis and treatment of chronic obstructive pulmonary disease (2013 Revised Edition). Chin J Tuberc Respir Dis 2013;36:255-264.

GOLD Executive Committee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2013). Available from: http://www.goldcopd.com. [Last accessed on 2015 Sep 10].

Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 2002;9:191-7.

Church D, Haverstock D, Andriole VT. Moxifloxacin: A review of its safety profile based on worldwide clinical trials. J New Dev Clin Med 2000;18:205-23.

Hurd S. The impact of COPD on lung health worldwide: Epidemiology and incidence. Chest 2000;117 2 Suppl:1S-4S.

Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: A 2 year follow up study. Thorax 2004;59:387-95.

Snow V, Lascher S, Mottur-Pilson C; Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001;134:595-9.

Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: A metaanalysis of randomized controlled trials. Chest 2007;132:447-55.

Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64.

Feng Y, Jin F, Mu S, Shen H, Yang X, Wang Y, et al. Greatest International ANtiinfective Trial (GIANT) with moxifloxacin in the treatment of acute exacerbation of chronic bronchitis: Subanalysis of Chinese data of a global, multicenter, noninterventional study. Clin Epidemiol 2010;2:15-21.

Sethi S. Etiology and management of infections in chronic obstructive pulmonary disease. Clin Pulm Med 1999;6:327-32.

Downloads

Published

2015-09-24

How to Cite

1.
Zhang T, Chen P, Chen C, Kuang J, Wang C, Yan X, Yang X, Shao Y, Yang X. Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis: Moxifloxacin injection for AECB. Community Acquir Infect. 2015;2. Accessed May 3, 2025. https://www.hksmp.com/journals/cai/article/view/248

Issue

Vol. 2 (2015)

Section

Original Articles

Downloads

Download data is not yet available.

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.